RGX 202

Drug Profile

RGX 202

Alternative Names: RGX-202

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rgenix
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Creatine-transporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer
  • Preclinical Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 31 Jul 2018 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03597581)
  • 31 Jul 2018 Phase-I clinical trials in Gastrointestinal cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (PO) (NCT03597581)
  • 18 Apr 2018 Preclinical trials in Pancreatic cancer in USA (unspecified route) prior to April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top